Black Rock Inc. Candel Therapeutics, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 823,071 shares of CADL stock, worth $3.51 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

823,071

Previous 47,580 1629.87%

Holding current value

$3.51 Million

Previous $75,000 6704.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.68 - $14.0 $1.3 Million - $10.9 Million	775,491 Added 1629.87%	823,071 $5.1 Million
Q1 2024 May 10, 2024	SELL	$1.21 - $1.86 $2,063 - $3,171	-1,705 Reduced 3.46%	47,580 $75,000
Q4 2023 Feb 13, 2024	SELL	$0.68 - $1.47 $383 - $829	-564 Reduced 1.13%	49,285 $72,000
Q3 2023 Nov 13, 2023	SELL	$0.91 - $1.3 $1,796 - $2,566	-1,974 Reduced 3.81%	49,849 $45,000
Q2 2023 Aug 11, 2023	BUY	$1.2 - $1.78 $6,334 - $9,396	5,279 Added 11.34%	51,823 $65,000
Q1 2023 May 12, 2023	BUY	$1.35 - $2.72 $10,120 - $20,391	7,497 Added 19.2%	46,544 $62,000
Q4 2022 Feb 13, 2023	SELL	$1.48 - $3.2 $127,166 - $274,953	-85,923 Reduced 68.75%	39,047 $69,000
Q3 2022 Nov 14, 2022	SELL	$3.05 - $4.08 $13,441 - $17,980	-4,407 Reduced 3.41%	124,970 $393,000
Q2 2022 Aug 12, 2022	SELL	$3.13 - $5.56 $9,217 - $16,374	-2,945 Reduced 2.23%	129,377 $420,000
Q1 2022 May 12, 2022	BUY	$3.66 - $8.0 $64,811 - $141,664	17,708 Added 15.45%	132,322 $674,000
Q4 2021 Feb 10, 2022	BUY	$6.34 - $11.9 $585,105 - $1.1 Million	92,288 Added 413.37%	114,614 $896,000
Q3 2021 Nov 09, 2021	BUY	$5.75 - $11.21 $128,374 - $250,274	22,326 New	22,326 $242,000

Others Institutions Holding CADL

# of Institutions

Shares Held

6.43M

Call Options Held

109K

Put Options Held

130K

View Full List

About Candel Therapeutics, Inc.

Ticker CADL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,891,900
Market Cap $123M
Description
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...

More about CADL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account